Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP) Reduction
Last updated on July 2021Recruitment
- Recruitment Status
- Enrolling by invitation
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Glaucoma
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: The design of this preliminary pilot trial is a double-masked (blind), randomized, No Treatment-controlled, parallel group design.Masking: Triple (Participant, Investigator, Outcomes Assessor)Masking Description: The practitioner providing the OMT or No Treatment will not be involved in collecting data for each subject. The practitioner(s) and technicians collecting the data will not be involved in any aspect of the procedure performed (OMT or No Treatment) on the subjects.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The design of this preliminary pilot trial to be conducted is a double-masked (blind), randomized, No Treatment-controlled, parallel group design to determine the IOP-lowering efficacy and safety of a single osteopathic manipulative treatment (OMT) on intraocular pressure (IOP) in un-medicated confi...
The design of this preliminary pilot trial to be conducted is a double-masked (blind), randomized, No Treatment-controlled, parallel group design to determine the IOP-lowering efficacy and safety of a single osteopathic manipulative treatment (OMT) on intraocular pressure (IOP) in un-medicated confirmed ocular hypertensive (OHT), glaucoma suspect, or subjects who have been diagnosed with glaucoma but who have gone through a medically supervised medication washout period or 4 weeks. Potential subjects responding to recruitment who are currently on IOP lowering medication will be prescreened and if interested in proceeding will undergo a 4 week medication washout period. Potential subjects not on IOP lowering medication will proceed directly to the Baseline screening visit. All subjects will be seen for a Baseline Screening Visit followed by a second Baseline Enrollment Visit, during which subjects must satisfy all inclusion criteria and their IOP must qualify in at least one (1) eye, the same eye, at all time points. Qualified subjects will be scheduled for a Study Day 3 Visit. Subjects whose IOP still qualifies at the Visit 3 time point will be randomized in a 1:1 ratio to receive OMT or No Treatment followed by IOP measurements and +7.5 HR (4 PM [± 1 hour]) post-OMT or No Treatment. Follow-up visits will be conducted at Visit 4 (1 day following OMT vs No Treatment), and Visit 5 (1 week following OMT vs No Treatment). Both Visit 4 and Visit 5 will have IOP measured twice.
Tracking Information
- NCT #
- NCT03590249
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Hollis H King, DO, PhD University of California, San Diego